Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   37587   clinical trials with a EudraCT protocol, of which   6160   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2012-000101-69
    Sponsor's Protocol Code Number:EGD-EC-005
    National Competent Authority:Netherlands - Competent Authority
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2013-07-04
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedNetherlands - Competent Authority
    A.2EudraCT number2012-000101-69
    A.3Full title of the trial
    An exploratory, open label, single-arm study to evaluate the effect of Eligard® 6-month on biomarkers of disease in patients with metastatic prostate cancer.
    Een verkennend, open-label, enkel-arm onderzoek om het effect van Eligard®-6 maanden op ziekte-biomarkers bij patiënten met gemetastaseerde prostaatkanker te beoordelen.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study in patients with metastatic prostate cancer to assess how the drug Eligard®, affects certain markers in blood and urine, which are indicators for the disease.
    Een onderzoek in patiënten met uitgezaaid prostaatkanker om te bepalen hoe het geneesmiddel Eligard®, bepaalde markers in bloed en urine, die indicatief zijn voor de ziekte, beinvloedt.
    A.3.2Name or abbreviated title of the trial where available
    EFFECT study
    EFFECT studie
    A.4.1Sponsor's protocol code numberEGD-EC-005
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAstellas Pharma Europe Ltd. (APEL)
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstellas Pharma Europe Ltd. (APEL)
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGlobal Development Operations
    B.5.2Functional name of contact pointService Desk
    B.5.3 Address:
    B.5.3.1Street AddressSylviusweg 62
    B.5.3.2Town/ cityLeiden
    B.5.3.3Post code2333 BE
    B.5.4Telephone number0031715455878
    B.5.5Fax number0031715455224
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D. name Eligard 45 mg
    D. of the Marketing Authorisation holderAstellas Pharma Europe B.V.
    D.2.1.2Country which granted the Marketing AuthorisationNetherlands
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients with metastatic prostate cancer whom androgen deprivation therapy (ADT) is indicated
    Patiënten met gemetastaseerde prostaatkanker voor wie androgeen deprivatie therapie (ADT) wordt voorgeschreven.
    E.1.1.1Medical condition in easily understood language
    Patients with metastatic prostate cancer
    Patiënten met gemetastaseerde prostaatkanker
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 17.0
    E.1.2Level LLT
    E.1.2Classification code 10007113
    E.1.2Term Cancer of prostate
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To explore the effect of Eligard® on the following prostate cancer biomarkers:
    • Testosterone in serum
    • Prostate Specific Antigen (PSA) in serum
    • Prostate Cancer Antigen (PCA3) in urine
    • PSA mRNA in blood/PBMC
    • PCA3 mRNA in blood/PBMC
    • TMPRSS2-ERG mRNA in blood/PBMC

    A blood sample for RNA analysis will also be collected and stored for future investigation in patients who have given informed consent for these samples to be collected.
    Om het effect van Eligard® op de volgende prostaatkanker biomarkers te onderzoeken:
    - Testosteron in serum
    - Prostaat Specifiek Antigeen (PSA) in serum
    - Prostaat Kanker Antigeen (PCA3 score) in urine
    - PSA mRNA in bloed/PBMC
    - PCA3 mRNA in bloed/PBMC
    - TMPRSS2-ERG mRNA in bloed/PBMC

    Een bloedmonster voor toekomstig RNA analyse zal worden afgenomen en opgeslagen van patiënten die daar een apart informed consent voor geven.
    E.2.2Secondary objectives of the trial
    Not applicable
    Niet van toepassing
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Male aged 18 years or older.
    2. Confirmed metastatic prostate cancer for whom androgen deprivation therapy (ADT) is indicated.
    3. Non-castrate level of serum testosterone (≥ 8 nmol/L (i.e.230 ng/dL)) at screening.
    4. Serum PSA ≥ 5 ng/mL at screening.
    5. Eastern Cooperative Oncology Group (ECOG) score of 0-2
    6. A life expectancy of at least 12 months.
    7. Is able to tolerate injections of study drug and comply with the study requirements.
    8. Positive blood PSA mRNA at screening. A positive PSA mRNA in PBMCs (defined as exceeding the Limit of Detection for the central lab assay, i.e. ≥ 10 copies per PCR).
    9. Patient has given written informed consent
    1. Man van 18 jaar of ouder.
    2. Bevestigde uitgezaaide prostaatkanker voor wie androgeen deprivatie therapie (ADT) wordt voorgeschreven.
    3. Niet-castratie niveau van serum testosteron (≥ 8 nmol/L (i.e. 230 ng/dL)) bij screening.
    4. Serum PSA ≥ 5 ng/mL bij screening.
    5. Eastern Cooperative Oncology Group (ECOG) score van 0-2.
    6. Een levensverwachting van tenminste 12 maanden.
    7. Is in staat om injecties van het bestudeerde geneesmiddel te tolereren en te voldoen aan de studie eisen.
    8. Positief PSA mRNA in bloed bij screening. Een positief PSA mRNA in PBMCs (gedefinieerd als signaal > Limit of Detection van de centrale labtest i.e. ≥ 10 kopieën per PCR).
    9. Patiënt heeft schriftelijk toestemming gegeven (informed consent).
    E.4Principal exclusion criteria
    1. History of bilateral orchidectomy.
    2. History of any hormonal treatment/therapy with GnRH agonist, GnRH anti-agonist within 6 months of enrolment.
    3. Treatment with anti-androgens (except where used to prevent testosterone flare up, starting up to 2 weeks prior to Eligard injection, according to local treatment guidelines), 5-α reductase inhibitors, estrogens and/or other any investigational hormone-derivative within 3 months of enrolment or 5-times the half-life, whichever is longer.
    4. Any previous treatment with chemotherapy treatment for prostate cancer prior to the screening visit or within 6 months prior to screening for any other cancer.
    5. Patients previously treated for cancer with hormonal therapy in whom treatment was stopped due to lack of efficacy, progression of the disease or lack of tolerability.
    6. Previous treatments for cancer (including prostate cancer) within 6 months prior to enrolment: immunotherapy, external beam radiotherapy, brachytherapy, thermotherapy, or biological response modifiers (e.g. cytokines).
    7. Known or suspected spinal cord compression or evidence of spinal metastases with risk of spinal compression,
    8. Uni- or bilateral uretric obstruction.
    9. Requiring concomitant use of anti-androgens during the course of the study (except where used to prevent testosterone flare up, starting up to 2 weeks prior to Eligard injection and continuing for up to 3 weeks, according to local treatment guidelines).
    10. Previous or concomitant malignancies at other sites except effectively treated non-melanoma skin cancer or an effectively treated malignancy that has been in remission for at least 5 years.
    11. Major surgery within 2 months prior to enrolment.
    12. Absolute neutrophil count < 1,500/μL, platelet count < 100,000/μL, and hemoglobin < 5.6 mmol/L (9 g/dL) at screening.
    13. Total bilirubin > 1.5 times the upper limit of normal (ULN) at screening. This will not apply to subjects with Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of hemolysis or hepatic pathology), who will be allowed in consultation with the sponsor.
    14. Alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) > 2 times ULN at screening.
    15. Creatinine > 177 μmol/L (2 mg/dL) at screening.
    16. Albumin ≤ 30 g/L (3.0 g/dL) at screening.
    17. Any clinical condition, diagnosis, symptomatology or ongoing investigation, which, in the opinion of the Investigator, contraindicates their participation in this study.
    18. Participation in any clinical study within ≤ 1 month prior to screening (or 5 half lives of the drugs under investigation, whichever is greater).
    19. Not available for follow-up assessments or unable to comply with study requirements.
    20. Known or suspected hypersensitivity to leuprorelin acetate, to other GnRH agonist or to
    any of the excipients of Eligard.
    21. Male subjects who are intending to donate sperm within 9 months following the injection of Eligard
    22. Male subjects and their female spouses/partners who are of childbearing potential and
    are NOT using highly effective contraception consisting of two forms of birth control
    (one of which must be a barrier method) starting at Screening and continuing for
    9 months from the time of the Eligard injection. Acceptable forms include:
    i. Established use of oral, injected or implanted hormonal methods of contraception.
    ii. Placement of an intrauterine device (IUD) or intrauterine system (IUS).
    iii.Barrier methods of contraception: Condom OR Occlusive cap (diaphragm or
    cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
    1. Voorgeschiedenis van bilaterale orchidectomie.
    2. Voorgeschiedenis van hormonale behandeling/therapie met een GnRH-agonist, GnRH anti-agonist binnen 6 maanden voor insluiting.
    3. Behandeling met anti-androgenen (behalve wanneer dit dient om een testosteron flare te voorkomen en er tot 2 weken voor de Eligard injectie mee wordt gestart, volgens lokale richtlijnen) , 5-α-reductaseremmers, oestrogenen en/of elk experimentele hormonale derivaat binnen 3 maanden voor insluiting of 5 maal de halfwaardetijd, welke het langste is.
    4. Een eerdere behandeling met chemotherapie voor prostaatkanker voorafgaand aan het screeningsbezoek of binnen 6 maanden voorafgaand aan de screening voor elke andere vorm van kanker.
    5. Patiënten die eerder behandeld zijn voor kanker met hormonale therapie bij wie de behandeling werd gestopt wegens gebrek aan werkzaamheid, progressie van de ziekte of gebrek aan verdraagzaamheid.
    6. Eerdere behandelingen voor kanker (met inbegrip van prostaatkanker) binnen 6 maanden voorafgaand aan de insluiting: immunotherapie, uitwendige bestraling, brachytherapie, thermotherapie of biologische response modifiers (bijvoorbeeld cytokines).
    7. Bekende of verdachte compressie van het ruggenmerg of tekenen van spinale metastasen met het risico van compressie van het ruggenmerg.
    8. Uni- of bilaterale urineweg obstructie.
    9. Noodzaak van gelijktijdig gebruik van anti-androgenen tijdens de studie (behalve wanneer dit dient om een testosteron flare te voorkomen, er tot twee weken voor de Eligard injectie mee wordt gestart en tot 3 weken wordt voortgezet, volgens lokale richtlijnen).
    10. Eerdere of huidige andere maligniteiten, behalve effectief behandelde non-melanoom huidkanker of een effectief behandelde maligniteit die in remissie is gedurende tenminste 5 jaar.
    11. Een grote operatie binnen 2 maanden voorafgaand aan de insluiting.
    12. Absoluut aantal neutrofielen (ANC) < 1.500/μL, aantal trombocyten < 100.000/μL, en hemoglobine < 5.6 mmol/L (9 g/dL) bij de screening.
    13. Totaal bilirubine > 1.5 keer de bovengrens van de normaal waarde (ULN) bij screening. Dit zal niet van toepassing zijn op proefpersonen met het syndroom van Gilbert (aanhoudende of terugkerende hyperbilirubinemie die voornamelijk ongeconjugeerd is in de afwezigheid van bewijs voor hemolyse of lever pathologie), wie worden toegestaan in overleg met de sponsor.
    14. Alanine aminotransferase (ALAT) of aspartaat aminotransferase (ASAT) > 2 maal de ULN bij de screening.
    15. Creatinine > 177 μml/L (2 mg/dL) bij screening.
    16. Albumine ≤ 30 g/L (3.0 g/dL) bij screening.
    17. Elke klinische conditie, diagnose, symptomen of lopend onderzoek, dat, naar het oordeel van de onderzoeker, een contra-indicatie vormt voor hun deelname aan deze studie.
    18. Deelname aan een klinische studie binnen 1 maand voorafgaand aan de screening (of 5 maal de halfwaardetijd van de onderzochte geneesmiddelen, welke groter is.
    19. Niet beschikbaar voor follow-up bezoeken/evaluaties of niet in staat om te voldoen aan de onderzoekseisen.
    20. Bekende of vermoede overgevoeligheid voor leuprorelineacetaat, andere GnRH agonisten of een van de hulpstoffen van Eligard.
    21. Mannelijke proefpersonen die van plan zijn om sperma te doneren binnen 9 maanden na de injectie van Eligard.
    22. Mannelijke proefpersonen en hun vrouwelijke echtgenoten/partners die in de vruchtbare leeftijd zijn en GEEN gebruik maken van een zeer effectieve anticonceptie methode, bestaande uit twee vormen van anticonceptie (waarvan er één een barrière methode moet zijn) vanaf screening en voortgezet gedurende 9 maanden vanaf het moment van de Eligard injectie. Aanvaardbare vormen omvatten:
    i. Langdurig gebruik van orale, ingespoten of ingebrachte hormonale anticonceptie methoden.
    ii. Het plaatsen van een spiraaltje (IUD) of intra-uterien systeem (IUS).
    iii. Barrière anticonceptie methoden: condoom of occlusieve cap (diafragma of cervicale/afsluiting caps) met zaaddodend schuim/gel/film/crème/zetpil.
    E.5 End points
    E.5.1Primary end point(s)
    Biomarker: Changes from baseline of the following biomarker variables:

    ● Testosterone levels in serum
    ● PSA level in serum
    ● PCA3 score in urine
    ● Number of PSA mRNA copies in blood/PBMC
    ● Number of PCA3 mRNA copies in blood/PBMC
    ● Number of TMPRSS2-ERG mRNA copies in blood/PBMC

    Safety: Reported treatment-emergent adverse events, including the grading according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.3).
    Biomarker: verandering ten opzichte van baseline van de volgende biomarker variabelen:

    - Testosteron levels in serum
    - PSA level in serum
    - PCA3 score in urine
    - Aantal PSA mRNA kopieën in bloed/PBMC
    - Aantal PCA3 mRNA kopieën in bloed/PBMC
    - Aantal TMPRSS2-ERG mRNA kopieën in bloed/PBMC

    Gerapporteerde bijwerkingen (gestart na behandeling met Eligard), inclusief de gradering volgens de gemeenschappelijke terminologie Criteria voor Adverse Events (CTCAE), versie 4.0.3.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Up to 24 weeks.
    Tot en met 24 weken.
    E.5.2Secondary end point(s)
    Not applicable.
    Niet van toepassing.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Not applicable.
    Niet van toepassing.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy No
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Exploratory Biomarkers
    Verkennende biomarkers.
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End trial will be when the last subject has completed last visit at week 24;


    When the sponsor is aware of information on matters concerning the quality, efficacy, and safety of the study drugs, as well as other important information that may affect proper conduct of the clinical study, the sponsor may discontinue the clinical study and send a written notice of the discontinuation along with the reasons to the investigator.
    Het einde van het onderzoek zal zijn wanneer de laatste patiënt zijn laatste bezoek in week 24 heeft voltooid.


    Als de sponsor op de hoogte is van informatie over zaken met betrekking tot de kwaliteit, de effectiviteit, en de veiligheid van de studiemedicatie, of andere belangrijke informatie dat een goed verloop van het klinisch onderzoek kan beïnvloeden, mag de sponsor het klinisch onderzoek beëindigen en zal de onderzoeker schriftelijk op de hoogte brengen hiervan met de redenen.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 25
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 25
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state50
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-07-04
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-06-03
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice